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ABSTRACT
The development of a new medicine is a process that requires enormous time and tremendous financing. It takes 10-15 years from 
the discovery of an active compound to the launch of its production and the start of drug marketing with the total costs of the 
project reaching 1.8 billion US dollars. These large time and financial costs stem from repeated testing and elimination of a large 
percentage of compounds over the course of screening at each stage of preclinical and clinical trials. Many investors have lost 
interest in financing new drug discovery projects (or pharmaceutical start-up companies) due to the high risk and extensive time 
required to produce a return on investments. Since all the research data are considered confidential by pharmaceutical companies 
and thus never shared with scientific community, different scientific groups waste significant resources repeating the same costly 
experiments in drug discovery. In this article, we discuss new approaches to drug discovery involving open access to the research 
data and alternative financing that could significantly streamline the search for new cures for human diseases.
Proposals for open access to scientific data in drug 
development 
The data collected in the course of drug development 
projects in pharmaceutical companies are confidential 
and are not shared within scientific community. That of-
ten leads to repetition of the efforts of various research 
groups in different companies. Open access publication 
of these data would save the costs of the synthesis and 
testing of compounds that have already been tested by 
other scientists. The prospect of significant resource 
savings exists – it is the development of new drugs in an 
open access format [1]. 
Large pharmaceutical corporations often collaborate 
with small innovative firms or academic groups and ac-
quire rights to new substances or technologies. This ap-
proach is called open innovation. It is certainly a step 
forward compared to the development of a drug within a 
single firm, but the number of researchers with access to 
information remains limited.
Recently, there are more attempts to open the access 
to research data in drug development to scientific com-
munity. This approach is especially effective at the early 
stages of drug discovery, when scientists are searching 
for and validating new targets [2]. 
A striking example is the Structural Genomics Con-
sortium (SGC) that was founded in 2003. According to the 
SGC rules, the general public has free access to all the 
results including the DNA sequences and the structures 
of the chemical compounds obtained by scientists par-
ticipating in the project. SGC has received the support 
of hundreds of companies and academic groups. Thanks 
to this project, the scientific community today has the 
opportunity to work with thousands of interesting sub-
stances and samples. Hundreds of articles have been 
published, that, for example, led to discovery of selective 
inhibitors for G9a-like protein (GLP) lysine methyltrans-
ferase [3]. One of the successful examples of collaboration 
between SGC and GlaxoSmithKline is development of the 
free web-based interactive tools WONKA and OOMMPPAA 
that help to analyze the protein-ligand interactions us-
ing computation chemistry approach [4]. Another exam-
ple of successful collaboration between GlaxoSmithKline 
and SGC is the study of JQ1 – an inhibitor of Bromodo-
main and Extra-Terminal motif (BET) family of bromo-
domain proteins – in cell and animal models. Results of 
this project were shared with scientific community and 
the inhibitor became available to other research groups. 
That facilitated the launch of several research programs 
in biopharmaceutical companies. These programs were 
focused on search for the new BET inhibitors with anti-
cancer, immunosuppressive and other medicinal effects. 
Some of these programs resulted in discovery of new 
structurally related potent BET inhibitors and led to a 
number of ongoing clinical trials [5]. 
It is particularly interesting that open research projects, 
especially those that focus on searching for a therapy for 
rare diseases, are often financed by groups of patients and 
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their relatives. One of the examples of the rare diseases 
is progressive ossifying fibrodysplasia (fibrodysplasia os-
sificans progressiva, FOP), also known as second skeleton 
disease, or one of the forms of glycogenase type IV (adult 
polyglucosan body disease, APBD), which are often fatal or 
lead to the disability of the patient. However, the number of 
people suffering from these diseases is small (hundreds or 
thousands in the world), which makes these areas of drug 
development unprofitable for pharmaceutical companies. 
The collaboration between the patients’ groups and scien-
tists could lead to significant acceleration of drug discovery 
and development process for this class of drugs. 
There are a number of successful examples of col-
laborations between the patients’ advocacy groups such 
as the Michael J. Fox Foundation for Parkinson’s Disease 
Research and the Cystic Fibrosis Foundation and bio-
pharmaceutical companies. These public organizations 
finance the initial research programs in biopharmaceu-
tical companies, provide access to the corresponding 
disease experts and help with clinical trials recruitment. 
Financing of the first stage of drug discovery process and 
supporting the data sharing throughout the whole pro-
cess both significantly help to accelerate the develop-
ment of new drugs for rare diseases [6]. 
Open platforms for the discovery of therapeutic 
targets
Several scientific organizations and pharmaceutical 
companies including Biogen, The European Molecular 
Biology Laboratory – European Bioinformatics Insti-
tute (EMBL-EBI), GlaxoSmithKline, and Welcome Trust 
Sanger Institute have recently created an open platform 
Open Targets for the discovery and validation of new 
therapeutic targets [7]. 
This platform enables open access to genomics, pro-
teomics, the results of traditional biochemical experi-
ments, animal models for corresponding diseases, clini-
cal data, etc. in order to find and validate certain targets 
(genes or proteins) as the first step in the course of the 
drug discovery process for the corresponding disease. 
Antibiotics and open access
Antibiotic resistance in the past few decades has pro-
duced a real health crisis. Uncontrolled use of these 
drugs in medicine and agriculture has led to a selection 
of resistant microorganisms. At the same time, the rate 
of discovery of new antibiotics slowed down significantly.
There are some economic reasons for that: the expen-
diture of time and money for the discovery and develop-
ment of new drugs is very high while the potential profits 
from antibiotics are low compared with so-called block-
buster drugs, e.g. Viagra®. On the other hand, “all the 
low-hanging fruit has already been ripped off” [8]. Most 
known classes of antibiotics were discovered in the 1950-
1970s as a result of screening of natural products. Today, 
in order to find new active compounds, scientists have to 
work with microorganisms that were previously unculti-
vated. In addition, the general drawback of all “natural” 
antibiotics is that they are likely to have mechanisms of 
resistance already.
However, millions of compounds that are not found 
in nature and have never been tested for antimicrobial 
activity have already been synthesized in chemical labs 
around the world. The Chemical Abstract Service (CAS) 
has around   100  million organic compounds registered 
[9]. Chemists in universities and industrial scientific lab-
oratories synthesize thousands of new compounds every 
year. For the most part, these products are not designed 
as drug candidates, but are rather synthesized for other 
purposes, e.g. to develop new methods of organic synthe-
sis. Therefore, unlike the libraries of substances created 
by pharmaceutical companies specifically to search for 
certain types of medicines, their diversity is practically 
unlimited. For example, if you apply to the collection of 
all the CAS registered organic compounds the general set 
of physicochemical restrictions for antimicrobials (MW 
<1200 Da and log P between -10 and 2) [10] about one 
third of all the compounds will be selected for the fur-
ther screening. Are there any promising new antibiotics 
among all this diversity?
In order to answer this question, the community for 
the antimicrobial drug discovery that is based on the 
principles of free access to research data was established, 
Community for Open Antimicrobial Drug Discovery (CO-
ADD). This organization is funded by the Welcome Trust 
and the University of Queensland (Brisbane, Australia) [9].
Any chemist in the world can send samples that will 
be tested free of charge for activity against several key 
microbial pathogens, cytotoxicity and protein binding. 
In addition, some other properties of these compounds, 
which are important for their antimicrobial activity, will 
be studied. All the expenses for weighing, packaging, and 
shipment of the samples are covered by CO-ADD. If a 
prospective antimicrobial compound is found, its further 
optimization requires funding through various grants.
All the compounds included in this program are test-
ed by the same standard methods, which is important 
for comparing the results. Moreover, negative results are 
considered to be as important as the positive ones. As 
the data accumulates, the value of this program will only 
increase as it becomes possible to establish new correla-
tions between the structure of various compounds and 
their properties such as antimicrobial activity, ability to 
penetrate into microbial cells, and cytotoxicity.
In order to attract to the project as many scientists 
as possible, CO-ADD uses advertising and search engine 
optimization (Google AdWords), social networks as well 
as campaigns in the media [11]. 
One of the successful examples of CO-ADD coopera-
tion with Russian research organizations is its collabo-
ration with the Zelinsky Institute of Organic Chemistry, 
Russian Academy of Sciences (ZIOC RAS). Scientists 
from this institute agreed to provide the CO-ADD with 
150,000 substances selected using nuclear magnetic res-
onance for screening. Of these, 35,520 substances have 
already been shipped for testing and several “hits” – sub-
stances with interesting antimicrobial activity and se-
lectivity – have been discovered. That marks the starting 
point for the further optimization of the molecular struc-
ture of the drug candidate. 
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Open access drug development and intellectual 
property
Intellectual property is an important source of income for 
universities and pharmaceutical companies. At present, al-
most every university has a patent office, which is extremely 
reluctant to share research results. Usually this requires the 
negotiation of contracts, which can take several months.
CO-ADD offers a reasonable compromise between 
the protection of intellectual property and open access 
to scientific data. After testing, the researchers have one 
and a half years to file a patent for their compound (if 
necessary, this term can be extended by mutual agree-
ment). After that, the scientists are required to provide a 
publication for an open access database.
CONCLUSIONS
Restrictions in the free distribution of information in 
drug development, including the patent system can slow 
down drug discovery efforts. At the same time, it is im-
perative to expedite the search for new antibiotics and 
cures for various lethal diseases. For example, there are 
well-known legal proceedings related to the patenting 
of human DNA sections, particularly genes responsible 
for the oncological diseases [12]. The time and resources 
spent by universities, pharmaceutical companies, and 
scientists for legal cases in patent courts, which are 
caused by the existing system of research data confiden-
tiality, probably could be used much more effectively. 
The open access approach to research data in drug 
discovery and development projects has significant eco-
nomic prospects. Most importantly, it enables small in-
stitutions and firms, start-up companies, researchers, 
non-profit organizations, and other interested parties 
around the world to take part in the scientific process 
that is focused on an extremely important goal – sup-
porting the life and health of all humans.
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